VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Consensus Rating of “Reduce” by Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been given a consensus rating of “Reduce” by the five research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $0.95.

VTGN has been the subject of a number of research analyst reports. Wall Street Zen cut VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd.

Institutional Investors Weigh In On VistaGen Therapeutics

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in shares of VistaGen Therapeutics in the 4th quarter valued at about $25,000. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics during the first quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of VistaGen Therapeutics during the third quarter worth about $39,000. Seven Fleet Capital Management LP bought a new position in shares of VistaGen Therapeutics during the fourth quarter worth about $42,000. Finally, Tudor Investment Corp ET AL bought a new position in shares of VistaGen Therapeutics during the fourth quarter worth about $50,000. Institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Stock Up 6.1%

Shares of NASDAQ VTGN opened at $0.25 on Friday. The company’s fifty day moving average is $0.56 and its 200-day moving average is $0.59. The stock has a market cap of $10.22 million, a price-to-earnings ratio of -0.14 and a beta of 0.40. VistaGen Therapeutics has a twelve month low of $0.20 and a twelve month high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Monday, June 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03). VistaGen Therapeutics had a negative net margin of 5,487.01% and a negative return on equity of 133.02%. The firm had revenue of $0.38 million during the quarter, compared to analyst estimates of $0.40 million. During the same period last year, the firm earned ($1.67) EPS. On average, research analysts anticipate that VistaGen Therapeutics will post -1.32 EPS for the current fiscal year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.